Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment

scientific article published on 01 December 2018

Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S11523-018-0611-0
P932PMC publication ID6876618
P698PubMed publication ID30536163

P50authorUlka VaishampayanQ86981393
P2093author name stringHarsh Shah
P2860cites workApalutamide Treatment and Metastasis-free Survival in Prostate CancerQ50053735
Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomesQ50244769
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.Q52598610
Apalutamide: First Global Approval.Q52601554
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.Q52660703
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.Q52679667
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.Q54218117
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trialQ56804990
Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancerQ88320357
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!Q88758400
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerQ89290059
Abiraterone in metastatic prostate cancer without previous chemotherapyQ24612084
Therapy escape mechanisms in the malignant prostateQ26795611
Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failureQ26859201
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerQ27853062
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerQ29616218
Alpha emitter radium-223 and survival in metastatic prostate cancerQ29617472
Increased survival with enzalutamide in prostate cancer after chemotherapyQ29617511
Abiraterone and increased survival in metastatic prostate cancerQ29617512
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialQ29620155
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerQ30278902
ERG induces taxane resistance in castration-resistant prostate cancerQ30602046
ARN-509: a novel antiandrogen for prostate cancer treatmentQ34248790
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 studyQ34415540
Enzalutamide in metastatic prostate cancer before chemotherapyQ34422206
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancerQ34467551
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapiesQ34483362
Darolutamide (ODM-201) for the treatment of prostate cancerQ34556466
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerQ35956276
Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive reviewQ35969717
Androgen deprivation therapy for prostate cancerQ36193125
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceQ36470627
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialQ36707077
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling timeQ37227675
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancerQ38681509
The evolving role of enzalutamide on the treatment of prostate cancerQ38720976
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerQ38746278
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancerQ38858948
Androgen Signaling in Prostate CancerQ39227656
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.Q40173819
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 TrialQ40270987
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialQ40950557
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).Q43668313
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancerQ44222779
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancerQ46463184
Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent diseaseQ47781853
P433issue6
P921main subjectprostate cancerQ181257
P304page(s)679-689
P577publication date2018-12-01
P1433published inTargeted oncologyQ25378200
P1476titleTherapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment
P478volume13

Reverse relations

Q61808652Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancercites workP2860

Search more.